The translation of stem cell therapies begins with a well-characterized and thoroughly documented starting cell source. REPROCELL’s StemRNA™ Clinical iPSC Seed Stock Clones offer cell therapy developers streamlined starting material that provides a gateway into early-stage clinical development. By combining regulatory alignment with ethical sourcing and footprint-free mRNA reprogramming, REPROCELL now offers various male and female, ready-to-use, clinical-grade iPSC lines manufactured in our facilities, in the U.S. and Japan. [Read more…]
Japan Moves Toward Permitting Fertilized Embryo Research Using iPSC-Derived Eggs and Sperm
A Japanese government bioethics panel has given the green light to a controversial but closely regulated area of research: the creation of human embryos using lab-generated sperm and eggs derived from pluripotent stem cells, including induced pluripotent stem (iPS) cells. The panel’s recommendation allows this practice strictly for scientific research focused on infertility and genetic diseases—not for reproductive purposes. [Read more…]
First-in-Human Trial of OpCT-001: An iPSC-Derived Cell Therapy for Primary Photoreceptor Diseases
-
OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor diseases
-
Phase 1/2a trial, CLARICO, is a first-in-human, multisite, 2-part interventional trial to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001
-
Primary photoreceptor diseases are a subgroup of inherited retinal disorders that affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in children and adults
uBriGene Launches Clinical iPSC Banks to Accelerate Regenerative Medicine and Cell Therapy Development
ROCKVILLE, MD, June 16, 2025 – uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced pluripotent stem cell (iPSC) banks. Developed using uBriGene’s proprietary RNA-LNP reprogramming technology, these iPSC banks are now available to support research, translational development, and clinical applications worldwide. [Read more…]
iPSC Technology Grows Even More Powerful and Disruptive
Since the discovery and development of induced pluripotent stem cell (iPSC or iPS cell) technology a decade ago, significant progress has been made within stem cell biology and regenerative medicine. In recent years, iPSCs have been used extensively in disease modeling, drug discovery, and cell therapy applications. Importantly, new pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and clinical trials employing human iPSC-derived cell types have been initiated. [Read more…]
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 79
- Next Page »